Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US

Gregory F. Guzauskas, Anthony Masaquel, Carolina Reyes, Coen Bernaards, Tania Krivasi, David L. Veenstra
  • Journal of Medical Economics, July 2018, Taylor & Francis
  • DOI: 10.1080/13696998.2018.1489254

The authors haven't yet claimed this publication.

Read Publication

http://dx.doi.org/10.1080/13696998.2018.1489254

In partnership with: